The Asia-Pacific Neurotherapeutics Market was worth $ xx Billion in 2018 and estimated to reach $ xx Billion by the end of 2023 with a growing potential of xxx %. Asia-Pacific market is regarded as an emerging market due to strong economic growth in many developing countries such as china, India, Malaysia.
Neurological disorders results in damage to the brain, spinal nerves that is caused by injury or illness. These disorders can affect men and women, young and old and people from all cultures at any stage of their life. Most of these disorders involve progressive decline in physical and mental capabilities that disrupts patient’s life. So the changes in the activity of brain can be witnessed due to brain injury, genetic disorders, changing lifestyle and other traumas. Patients suffering from these disorders witnessed varied symptoms such as paralysis, muscle weakness, pain and other disorders. Hence, Neurotherapeutics are used for the treatment of various neurologic disorders.
The factors that are driving the growth of Asia-Pacific Neurotherapeutics Market are increasing aging population, growing R&D expenditure, a better understanding of the nature of neurologic diseases. Aged population are more susceptible to brain disorders. Therefore, the rise in aging population and life expectancy of the people will increase the market. Restrictions by regulatory bodies on various technologies and drugs, Lack of awareness in developing countries, lack of proper reimbursement policy are the factors that are hampering the growth of the market.
Based on Treatment, the market is segmented into Neurologic drugs and Neurologic devices. Neurologic drugs are further classified into oral administration, injections and others. Whereas neurologic devices are further categorized into Electroconvulsive Therapy (ECT), Vagus Nerve Stimulation (VNS), transcranial magnetic stimulation, Deep Brain Stimulator, and others. Based on disorders, the market is segmented into Central Nervous system (CNS) disorders, Peripheral Nervous system (PNS) disorders, Autonomous Nervous system (ANS) disorders. Based on distribution channels the market is segmented into Hospitals, Neurotherapeutic center, Clinical research organizations, Clinics. Based on Geography, the Asia-Pacific Neurotherapeutics market is analyzed under various regions namely China, Japan, India and Australia.
Some of the key Players dominating the Asia-pacific Neurotherapeutics Market are Abbott Laboratories, Inc., Becton, Novartis AG, Dickinson and Company, Pfizer, Inc., Johnson & Johnson, Biogen, Inc., GlaxoSmithKline, Inc., AstraZeneca plc, Sanofi-Aventis, Spiegelberg, stryker, Covidien, Medtronic, GE healthcare, and Merck & Co.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Treatment
5.1.1 Introduction
5.1.2 Neurologic Drugs
5.1.2.1 Oral Administration
5.1.2.2 Injections
5.1.2.3 Others
5.1.3 Neurologic Devices
5.1.3.1 Electroconvulsive Therapy (ECT)
5.1.3.2 Vagus Nerve Stimulation (VNS)
5.1.3.3 Transcranial magnetic stimulation
5.1.3.4 Deep Brain Stimulator
5.1.3.5 Others
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 Disorders
5.2.1 Introduction
5.2.2 Central Nervous system disorder
5.2.3 Peripheral Nervous system disorder
5.2.4 Autonomous Nervous system disorder
5.2.5 Y-o-Y Growth Analysis, By Type
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By Type
5.3 Distribution Channels
5.3.1 Introduction
5.3.2 Hospitals
5.3.3 Neurotherapeutic center
5.3.4 Clinical Research organisations
5.3.5 Clinics
5.3.6 Y-o-Y Growth Analysis, By Application
5.3.7 Market Attractiveness Analysis, By Application
5.3.8 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Treatment
6.1.3.3 By Disorders
6.1.3.4 By Distribution Channels
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Treatment
6.1.4.3 By Disorders
6.1.4.4 By Distributional Channels
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Treatment
6.1.5.3 By Disorders
6.1.5.4 By Distribution channels
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Becton
8.3 Novartis AG
8.4 Dickinson and Company
8.5 Pfizer
8.6 Johnson & Johnson
8.7 Biogen
8.8 Glaxosmithkline
8.9 AstraZeneca
8.10 Sanofi Aventis
8.11 Spiegelberg
8.12 Covidien
8.13 Medtronic
8.14 GE Health Care
8.15 Merck & Co
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
